Program
Acetaminophen
Also written as “Paracetamol”, “IV Acetaminophen” and “Experimental paracetamol formulation”.
Its studies are mostly in Pain · Pain, Postoperative · Migraine Disorders · Common Cold · Fever, led by 26 companies.
Drug pageAcetaminophen: every studyMany companies study it; this page follows only the 123 they lead. All 662 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 390 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| GlaxoSmithKlineits history only | 240 open or running | phase 4since Feb 18, 2010 | Jun 2, 2006 | none ahead |
| Keenova Therapeuticsits history only | 110 open or running | phase 4since Feb 5, 2016 | Nov 14, 2006 | none ahead |
| Allodynic Therapeuticsits history only | 60 open or running | phase 3since Jun 8, 2017 | Feb 17, 2017 | none ahead |
| Novartisits history only | 60 open or running | phase 4since Jun 19, 2007 | Jan 29, 2007 | none ahead |
| Sanofiits history only | 41 open or running | phase 3since Feb 12, 2007 | Feb 12, 2007 | May 17, 2027phase 2 · NCT06647407 |
| Sun Pharmaceutical Industriesits history only | 40 open or running | no phasesince Feb 18, 2010 | Feb 18, 2010 | none ahead |
| AFT Pharmaceuticalsits history only | 30 open or running | phase 3since Aug 16, 2011 | Aug 16, 2011 | none ahead |
| Nevakarits history only | 30 open or running | phase 2since Jul 8, 2019 | Jul 8, 2019 | none ahead |
| Angelini Pharmaits history only | 20 open or running | phase 2since Apr 9, 2015 | Apr 9, 2015 | none ahead |
| Baxter Healthcareits history only | 20 open or running | phase 3since Nov 29, 2006 | Nov 29, 2006 | none ahead |
| Grünenthalits history only | 20 open or running | phase 1since Apr 27, 2017 | Apr 27, 2017 | none ahead |
| Hamad Medicalits history only | 20 open or running | phase 4since Dec 12, 2019 | Jun 21, 2013 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 20 open or running | phase 3since Mar 3, 2025 | Jun 15, 2022 | none ahead |
| Sinteticaits history only | 20 open or running | phase 2since Dec 23, 2015 | Dec 23, 2015 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Aug 23, 2018 | Aug 23, 2018 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 1since Aug 24, 2018 | Aug 24, 2018 | none ahead |
| Boehringer Ingelheimits history only | 10 open or running | phase 3since Jul 7, 2014 | Jul 7, 2014 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 4since Jun 23, 2006 | Jun 23, 2006 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Oct 5, 2021 | Oct 5, 2021 | none ahead |
| HALEON | 10 open or running | phase 1since Feb 28, 2025 | Feb 28, 2025 | none ahead |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Par Healthits history only | 10 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| QC Kinetixits history only | 10 open or running | phase 2since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Reckittits history only | 10 open or running | phase 3since Oct 26, 2010 | Oct 26, 2010 | none ahead |
| Rottapharmits history only | 10 open or running | phase 3since May 9, 2005 | May 9, 2005 | none ahead |
Also a collaborator on its studies: Nevakar Injectables, Cross, Cross Research, Premier Research Group, Aptuit, MDS Pharma Services and PriCara, Unit of Ortho-McNeil.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of HALEON only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 28, 2025First study: phase 1 study in FeverFirst studyNCT06855576 · 54 enrolled · Germany
TargetBeta
“Cyclooxygenase inhibitor; Anandamide amidohydrolase inhibitor; Vanilloid receptor opener”ChEMBL 37, by rule
Studies
The one study HALEON leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06855576Fever · Germany | 1 | Completed | Apr 17, 2025 | 54 |
How it is read
Names in the registry
- “Acetaminophen”, 24 entries
- “Paracetamol”, 10 entries
- “IV Acetaminophen”, 10 entries
- “Experimental paracetamol formulation”, 5 entries
- “acetaminophen”, 5 entries
Conditions, from the studies’ own filings
- Pain, 28 studies
- Pain, Postoperative, 13 studies
- Migraine Disorders, 8 studies
- Common Cold, 7 studies
- Fever, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.